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Purpose: To assess patient-reported outcomes, including frequency of
nighttime heartburn symptoms, level of discomfort with nighttime heart-
burn symptoms, and quality of sleep, in patients with gastroesophageal
reflux disease (GERD).
Methods: Randomized, double-blind, baseline-controlled, two-period,
two-treatment crossover study. Placebo was administered during baseline
pH measurements. Patients were then randomly assigned to one of the
following sequences: pantoprazole/ranitidine (n12) or ranitidine/panto-
prazole (n19). Patients underwent two 8-day, double-blind treatment
periods (pantoprazole 40 mg once daily or ranitidine 150 mg twice daily)
separated by at least a 10-day (up to 21-day) washout period. Patients
recorded frequency of nighttime heartburn symptoms (number of episodes
per day), level of discomfort (1none to 7very severe) with nighttime
heartburn symptoms, and sleep quality (1excellent to 7extremely poor)
using daily diaries. Differences between pantoprazole and ranitidine were
compared using two-sample t-test or nonparametric Wilcoxon test as ap-
propriate. A P-value  0.05 in a two-tailed test was considered significant.
Results: On day 1 and 8 during the nighttime (10 pm-8 am) period, the
percentage of time that pH was 4 or higher was significantly greater with
pantoprazole versus ranitidine (P0.004 and P0.007, respectively). Re-
gardless of period: the frequency of nighttime heartburn symptoms was
0.170.37 for pantoprazole versus 0.500.55 for ranitidine (P0.01), the
level of discomfort with nighttime heartburn symptoms was 1.200.36 for
pantoprazole versus 1.620.64 for ranitidine (P0.01), and the quality of
sleep was 2.760.66 for pantoprazole versus 2.940.59 for ranitidine
(P0.05).
Conclusions: Pantoprazole has a significantly positive impact on patient-
reported outcomes including frequency of nighttime heartburn symptoms,
level of discomfort with nighttime heartburn symptoms, and quality of
sleep, in patients with GERD.
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VIRTUAL COLONOSCOPY; REAL MISSES
Aaron Link, M.D., Peter Cram, M.D., Ben Dwamena, M.D.,
John M. Inadomi, M.D.*. University of Michigan, Ann Arbor, MI;
University of Iowa, Iowa City, IA and VA Ann Arbor Healthcare
Systems, Ann Arbor, MI.
Purpose: Virtual colonoscopy (VC) may replace conventional colonos-
copy (CC) for colorectal cancer screening if the test characteristics of VC
are adequate. We performed a meta-analysis of studies comparing com-
puted tomography (CT) and magnetic resonance (MR) colonography with
CC for the detection of colon polyps and cancers.
Methods: Searches of published literature were performed on multiple
electronic databases (MEDLINE, PREMEDLINE, EMBASE, and others
from 1966 to March 2002) and cross-citation, independently by two authors
(A.L. and P.C.). Bibliographic search used specified key words including
(colonoscopy, colonography, colography, or pneumocolon) and (CT or
MRI). English language studies were selected if they evaluated at least 10
patients with either CT or MR colonography, using CC as the reference
standard for the detection of colon polyps and/or cancers. Articles were
excluded if the sensitivity and specificity of VC could not be calculated on
a per patient basis, or if they used computer-assisted interpretation without
radiologist interpretation. Two authors (A.L. and P.C.) independently re-
viewed and abstracted retrieved studies. Discrepancies in data collection
were resolved by consensus. Individual sensitivity and specificity were
calculated from contingency data for all selected studies, and separately for
MR and CT subgroups. Using the algorithmic meta-analysis method of
Midgette and colleagues, we performed weighted summary receiver oper-
ator characteristic curve (SROC) analyses if threshold effects were present
and calculated the area under the curve (AUC). Otherwise, we pooled test
characteristics using random effect models.
Results: Four hundred and forty-seven studies were identified by the
literature search, of which 16 met inclusion criteria, including 11 CT
studies of 1236 subjects, and 5 MR studies of 316 subjects. Mean sensi-
tivity and specificity were 0.73 (0.61–0.83) and 0.82 (0.72–0.89) respec-
tively for all studies. For CT mean sensitivity was 0.73 (0.57–0.85), mean
specificity was 0.81 (0.68–0.89). For MR mean sensitivity was 0.75
(0.47–0.91), mean specificity was 0.82 (0.73–0.89). The AUC was 0.81 for
all studies and for CT studies. Significant heterogeneity was noted that
might be explained by use of different diagnostic thresholds.
Conclusions: Compared to conventional colonoscopy, virtual colonoscopy
results in a 27% rate of missed colorectal lesions. Using current technology,
VC is not an adequate screening tool for colorectal cancer.
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THE STUDY FUNDING SOURCE IS ASSOCIATED WITH
STUDY QUALITY IN GI RESEARCH
Alphonso Brown, M.D., Sara Schmidt, B.A.*, Daniel Kraft, M.D.,
Chris Martin, Ph.D., Nicholas J. Shaheen, M.D. The University of
North Carolina at Chapel Hill, Chapel Hill, NC.
Purpose: Clinical research in GI is funded by various sources, including
private industry, municipalities and professional societies. The effect that
the source of the funding for a study has on the quality of the study is not
known. The aim of this study was to describe the association between
funding source and study quality in the clinical GI literature.
Methods: We reviewed all published articles in 4 leading GI journals
(Gastroenterology (Gastro), American Journal of Gastroenterology (AJG),
Hepatology (Hep), Gastrointestinal Endoscopy (GIENDO)) to assess fund-
ing source for GI research. All articles assessing the effectiveness of a drug
therapy or device were included. Data were abstracted on a standardized
form. Data abstracted included: journal reference, drug/device being as-
sessed, methodology score (0-100 scale), clinical question, funding source
and whether the study outcome favored continued use or identification.
Study quality was assessed using a modification of a previously validated
methodology scoring system. Quality was determined by assessing 5 at-
tributes: study type, randomization scheme, blinding scheme, whether the
study was controlled, and any of the following: sample size calculation,
intention to treat analysis or a survival analysis. Funding sources were
classified as industry-sponsored, federal/state government-sponsored, na-
tional society sponsored or not specified.
Results: A total of 317 papers met the inclusion criteria and underwent
abstraction (222 drug therapy papers, 93 device papers). The mean quality
of the papers was 65%. Papers published in the journals with the two
highest impact factors (Gastro and Hep) had an average methods score of
69% whereas studies published in the other two journals (AJG and
GIENDO) had a average methods score of 63%. Drug therapy papers
demonstrated significantly higher mean quality scores when compared to
device papers (67% vs. 60%, p .03). Research funded by federal/state
sources and research funded by academic professional societies had lower
quality than research funded by private industry (64% and 65% vs. 75%
respectively, p.00005).
Conclusions: The funding source of clinical GI research is a predictor of
study quality as assessed using a standardized method. Studies funded by
private industry tend to have higher quality scores than those funded by
governmental sources and professional societies.
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IDENTIFYING IBS PATIENTS USING ROME II SYMPTOM
CRITERIA: 3- OR 12-MONTH REPORTING?
Bonnie B. Dean, Ph.D., Daniel Aguilar, M.P.H.,
Victoria Barghout, M.S.P.H., Kristijan Kahler, R.Ph., S.M.,
David Groves, Ph.D., Joshua J. Ofman, M.D., M.S.H.S.*. Zynx Health
Incorporated, Los Angeles, CA; Novartis Pharmaceuticals Corporation,
East Hanover, NJ and Comerica Incorporated, Detroit, MI.
Purpose: To assess the agreement between 3- vs 12-month Rome II IBS
symptom criteria and to assess the agreement between the Rome criteria
and self-report of a previous medical diagnosis of irritable bowel syndrome
(IBS) in an employed U.S. population.
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